By looking at genes belonging to three canonical pathways (ERK/MAPK, PI3K/AKT, and “prostate cancer signaling”) specific differences in the modulatory effects induced by the three combinatorial treatments were identified (highlighted by red arrows in Figure 10 and Supplementary Figure 16A–16C). The gene discussed is AKT1; the disease is prostate carcinoma.